Kenneth E Simon

7465449, Dec 16, 2008

Mar 13, 2003

10/507662

Shelia M. Violette - Lexington MA, US
Paul H. Weinreb - Andover MA, US
Kenneth J. Simon - Cambridge MA, US
Dean Sheppard - Oakland CA, US
Diane R. Leone - Winchester MA, US

Biogen Idec MA Inc. - Cambridge MA
The Regents of the University of California - Oakland CA

A61K 39/395
G01N 33/53
C07K 16/28

4241431, 435 71, 53038822, 5303871

Monoclonal antibodies that specifically bind to M. 96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.

7678371, Mar 16, 2010

Mar 6, 2006

11/369641

Alexey Alexandrovich Lugovskoy - Woburn MA, US
Karl Hanf - Billerica MA, US
You Li - Newton MA, US
Kenneth Simon - Cambridge MA, US
Herman Van Vlijmen - Mechelen, BE

Biogen Idec MA Inc. - Cambridge MA

A61K 39/00

4241331, 5303871

The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.

7943742, May 17, 2011

Jul 10, 2006

11/483190

Shelia M. Violette - Lexington MA, US
Louise A. Koopman - Brookline MA, US
Kenneth J. Simon - Cambridge MA, US
Paul H. Weinreb - Andover MA, US
Herman W. T. van Vlijmen - Mechelen, BE
Jose W. Saldanha - Endfield, GB
Alexey A. Lugovskoy - Woburn MA, US

Biogen Idec MA Inc. - Cambridge MA

C12P 21/08
C07K 16/00
A61K 39/395
C12P 21/04

5303873, 5303881, 53038822, 5303888, 4241331, 4241411, 4241431, 4241551, 435 696, 435 7021

The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αβintegrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-αβantibodies of the invention. The invention also relates to the identification of differential expression of the integrin αβon the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin αβ.

8153126, Apr 10, 2012

Oct 29, 2008

12/260510

Shelia M. Violette - Lexington MA, US
Paul H. Weinreb - Andover MA, US
Kenneth J. Simon - Cambridge MA, US
Dean Sheppard - Oakland CA, US
Diane R. Leone - Winchester MA, US

A61K 39/395

4241331, 4241431

Monoclonal antibodies that specifically bind to □v□□. Also included are methods of using these antibodies to treat mammals having or at risk of having □v□6-mediated diseases, or to diagnose □V□6-mediated diseases.

8349324, Jan 8, 2013

Dec 1, 2009

12/628898

Alexey Alexandrovich Lugovskoy - Woburn MA, US
Karl Hanf - Billerica MA, US
You Li - Newton MA, US
Kenneth Simon - Cambridge MA, US
Herman Van Vlijmen - Mechelen, BE

Biogen Idec MA Inc. - Cambridge MA

A61K 39/395

4241331, 5303871

The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.

20060222644, Oct 5, 2006

Dec 23, 2004

11/021819

Ellen Garber - Cambridge MA, US
Kenneth Simon - Cambridge MA, US
Jose Saldanha - Enfield, GB

Biogen Idec MA Inc. - Cambridge MA

A61K 39/395
C12N 5/06
C07K 16/44

424141100, 530388150, 435328000

This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-β-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods.

20110305629, Dec 15, 2011

May 17, 2011

13/109168

Shelia M. Violette - Lexington MA, US
Louise A. Koopman - Brookline MA, US
Kenneth J. Simon - Cambridge MA, US
Paul H. Weinreb - Andover MA, US
Herman W.T. van Vlijmen - Mechelen, NL
Jose W. Saldanha - Endfield, GB
Alexey A. Lugovskoy - Woburn MA, US

BIOGEN IDEC MA INC. - Cambridge MA

A61K 39/395
A61K 51/10
A61P 35/04
A61K 51/00
A61P 17/06
A61P 35/00

424 149, 4241331, 4241781, 424 111

The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αβintegrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-αβantibodies of the invention. The invention also relates to the identification of differential expression of the integrin αβon the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin αβ.

20120251532, Oct 4, 2012

Apr 10, 2012

13/443261

Shelia M. Violette - Lexington MA, US
Paul H. Weinreb - Andover MA, US
Kenneth J. Simon - Cambridge MA, US
Dean Sheppard - Oakland CA, US
Diane R. Leone - Winchester MA, US

The Regents of the University of California, a California corporation - Oakland CA
BIOGEN IDEC MA INC. - Cambridge MA

A61K 39/395
A61P 17/06

4241331, 4241431, 4241781

Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.